DTAC is a buyer readiness exercise
The Digital Technology Assessment Criteria asks whether a product is clinically safe, technically secure, usable, accessible and aligned with NHS expectations.
The mistake is treating DTAC as a form-filling exercise. The better approach is to build a buyer assurance pack that answers the questions adoption and clinical teams will ask anyway.
Evidence should connect the story
Technical, clinical, risk, software, security and governance evidence should reinforce the same route-to-market story. When these artefacts are built separately, the file becomes harder to defend and harder to reuse.
A strong evidence plan makes regulatory review, buyer assurance and future expansion easier because it shows why the product is safe, effective, controlled and trustworthy.
Where teams usually get stuck
Clinical safety under DCB 0129, data protection evidence and security controls often mature at different speeds. DTAC exposes those gaps quickly.
Neural Vibe helps teams sequence the work so DTAC becomes a practical readiness path rather than a late-stage blocker.
DTAC is really five conversations happening at once
A DTAC assessment is often described as a checklist, but the domains represent different forms of confidence. Clinical safety asks whether the product can be used safely in care. Data protection asks whether personal data is handled lawfully and transparently. Technical security asks whether the service can be trusted. Usability and accessibility ask whether people can use it safely and fairly. Interoperability asks whether it fits the NHS environment.
Teams get into trouble when these conversations are handled by separate people at separate times. The evidence may be individually reasonable, but the overall story feels fragmented. A stronger DTAC pack shows that the product has been built, operated and monitored as one coherent health technology.
Clinical safety usually sets the pace
For manufacturers, DCB 0129 can become the pacing item because it requires real clinical risk thinking, not just a template. The hazard log, safety case, clinical safety officer input and release/change process need to connect to product decisions. If this work starts too late, it can expose questions that should have shaped the product earlier.
That is why DTAC readiness should begin with the product journey and clinical use case. Once the team understands where harm could occur, it becomes easier to connect safety, privacy, security, accessibility and support arrangements to the same user reality.
Buyers look for operational confidence
A buyer does not only want to know that a document exists. They want confidence that the organisation can operate the product responsibly after adoption. That includes incident response, vulnerability handling, release management, supplier control, data protection governance and clear clinical accountability.
The best DTAC evidence therefore reads like an operating model, not a paperwork archive. It shows what the team does, who owns it, how often it happens and how the product improves when real-world information arrives.
How to prepare without paperwork theatre
Start with a gap assessment against the product as it is actually built and sold. Then prioritise gaps that would block adoption or expose clinical risk. Policies and procedures should be written around real workflows, not invented as decorative compliance documents.
For startups and scale-ups, this is the difference between a DTAC exercise that drains the company and a readiness programme that strengthens the product. Done well, the evidence can support NHS adoption, enterprise sales, quality system maturity and future regulatory work at the same time.